Monitor early TRUTAKNA prescription/ revenue data over the next 2-4 quarters to gauge commercial traction. The key near-term catalysts are the ORIGIN 3 final efficacy analysis (Q3 2026), which could support full approval and label expansion, and the sBLA submission (Q4 2026).
Drug in focus
VERA drug pipeline →TRUTAKNA
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
- Next catalyst
- None dated
What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.
Price Chart
Executive Summary
Vera Therapeutics reported Q2 2026 earnings: net loss of $109.5M ($1.52/share) vs. $76.5M ($1.20/share) in Q2 2025, with operating cash burn of $206.8M in H1 2026. The FDA granted accelerated approval for TRUTAKNA (atacicept) in July 2026 for IgA nephropathy, and the U.S. commercial launch is underway. However, the company had no revenue, cash declined to $499.2M from $714.6M at year-end, and the per-share loss widened. The approval is a transformative event but the stock had already moved on the PDUFA date of July 7, 2026, so this filing itself is primarily an update on launch execution and financials.
Key Financial Metrics
Key Facts
- TRUTAKNA (atacicept) received FDA accelerated approval in July 2026 for primary IgA nephropathy; U.S. commercial launch is underway.
- Q2 2026 net loss of $109.5M, or $1.52 per share, vs. $76.5M, or $1.20 per share, in Q2 2025.
- Cash, cash equivalents, and marketable securities were $499.2M at June 30, 2026, plus up to $425M available under a debt facility.
- FDA alignment on earlier ORIGIN 3 final efficacy analysis to support potential full approval; results expected Q3 2026.
- Net cash used in operating activities was $206.8M for the six months ended June 30, 2026, vs. $109.2M for the same period in 2025.
- No revenue reported (pre-commercialization stage).
Financial Impact
Net loss of $109.5M in Q2 2026, widening from $76.5M in Q2 2025. Cash burn accelerated to $206.8M in H1 2026 from $109.2M in H1 2025. Despite the drug launch, cash declined by $215.4M from year-end 2025.
Risk Factors
- Commercial launch of TRUTAKNA may underperform expectations; patient uptake is unproven.
- Full approval of TRUTAKNA is contingent on positive ORIGIN 3 confirmatory data.
- Cash burn rate is high ($206.8M in H1); additional financing may be needed despite $499.2M cash + $425M debt facility.
- Competition in IgAN from other therapies (e.g., Tarpeyo, Filspari, and other BAFF/APRIL inhibitors in development).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342335 |
| Document: vera-20260810.htm | 0001193125-26-342335 |
| Document: 0001193125-26-342335-index-headers.html | 0001193125-26-342335 |
| Document: 0001193125-26-342335-index.html | 0001193125-26-342335 |
| Document: 0001193125-26-342335.txt | 0001193125-26-342335 |
| 8-K Data (Synthetic) | 0001193125-26-342335 |
Track record
25 reports on VERA
13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Viewing No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers